Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors. It offers treatment for adult patients with unresectable advanced/recurrent non-small cell lung cancer (NSCLC) who have progressed on or after platinum-based chemotherapy.

Optune Lua, a wearable, portable medical device, produces alternating electric fields called tumor-treating fields (TTFields). Delivered through non-invasive, wearable arrays, TTFields exert physical forces on the electrically charged components of dividing cancer cells. This results in cancer cell death.

At just 2.7 pounds (with a battery), it offers a wearable, portable option for continuing normal daily activities. The company designed it for enhanced carrying comfort and usability.